Core Viewpoint - The stock of Hongbo Pharmaceutical (301230) has experienced significant trading volatility, with a cumulative price deviation exceeding 30% over two consecutive trading days and over 100% over five trading days [1] Group 1: Stock Performance - The company's stock price has shown a cumulative deviation of over 30% in closing prices for two consecutive trading days [1] - Over a span of five trading days, the cumulative deviation in closing prices has exceeded 100% [1] Group 2: Company Operations - The company reports that its operations are normal and there have been no significant changes [1] - The direct revenue from the DiOrion platform drug development services constitutes a small portion of the company's overall revenue and does not significantly impact the overall business performance [1]

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) announced that the direct revenue from its DiOrion platform drug development services currently constitutes a small proportion of the company's overall operating income, and it does not significantly impact the company's overall business performance [1] Group 1 - The company reported unusual stock trading fluctuations and severe abnormal trading activity [1] - An internal review found no undisclosed significant information that could have impacted the stock price [1]

Core Viewpoint - The company, Hongbo Pharmaceutical, announced that its stock price experienced an abnormal fluctuation, with a cumulative increase of over 30% in closing prices over two consecutive trading days [1] Group 1: Company Operations - The company conducted a self-examination and confirmed that there are no undisclosed significant matters regarding its operations as of the announcement date [1] - The company's current operations are normal, and there have been no significant changes [1] Group 2: Revenue Impact - The direct revenue from the DiOrion platform's drug development services constitutes a small proportion of the company's overall revenue, thus not significantly impacting the overall business performance [1]

Core Viewpoint - The company, Hongbo Pharmaceutical, has experienced significant stock price fluctuations since January 8, 2026, with a cumulative increase surpassing most peers in the industry and significantly exceeding the growth of relevant indices such as the ChiNext Index, ChiNext 50, and Shenzhen Component Index [1] Group 1 - The company's stock price has shown a substantial increase, leading to a higher profit adjustment risk due to accumulated gains [1] - A self-examination was conducted by the company, and a letter was sent to the controlling shareholder and actual controller for verification, confirming no undisclosed significant matters related to the company as of the announcement date [1] - The company's operations are currently normal, with no significant changes reported [1] Group 2 - The direct revenue from the DiOrion platform's drug development services constitutes a small proportion of the company's overall operating income, indicating it does not significantly impact the overall business performance [1]

证券代码：301230 证券简称：泓博医药 公告编号：2026-003 上海泓博智源医药股份有限公司 关于股票交易异常波动及股票交易严重异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示 1、上海泓博智源医药股份有限公司（以下简称"公司"）股票交易价格于 2026 年 1 月 13 日、1 月 14 日连续两个交易日收盘价格涨幅偏离值累计超过 30%，根据《深圳 证券交易所交易规则》的相关规定，属于股票交易异常波动的情形；公司股票交易价格 于 2026 年 1 月 8 日至 2026 年 1 月 14 日连续五个交易日内日收盘价涨幅偏离值累计超 过 100%，根据《深圳证券交易所交易规则》的相关规定，属于股票交易严重异常波动 的情况。 2、公司自查，并向公司控股股东、实际控制人发函查证，截至本公告披露日，确 认不存在关于公司的应披露而未披露的重大事项。公司目前经营正常，未发生重大变化。 100%，根据《深圳证券交易所交易规则》的相关规定，属于股票交易严重异常波动的 情况。 二、公司关注并核实情况 针对公司股票交易异常波动，公司对有关事项进 ...

马斯克又开"预言家"模式了！这次直接把矛头对准外科医生，放话3年让擎天柱机器人干翻顶尖外科医 生，以后学医没用。不过，马斯克画饼画得飞起，医学界大佬们可坐不住了。 "定海神针"张文宏医生直接泼了盆冷水： 这边"人机大战"的口水仗还没分出胜负，那边AI医疗的热度已经被焊死在热搜上。网友虽然吵得不可开 交，但股民可没工夫等三年五载验证预言，反手就给AI医疗板块安排了一场"涨停大合唱"。泓博医药、 迪安诊断这些相关公司，五天涨幅直接翻倍，从上游算力、大模型，到中游医疗信息化，再到下游制 药、医院，整个产业链集体狂欢。 股民的心态简直真实到扎心：管它未来是机器抢医生饭碗，还是当医生的"超级外挂"，这波技术变革的 钱，先赚了再说！ 大佬们也没闲着，AI芯片一哥英伟达砸10亿美元重仓AI制药；OpenAI悄悄收购医疗数据公司，摆明要 打通医疗数据"任督二脉"。他们争夺的，是医疗AI时代的"水电煤"和"数据燃料。明眼人都懂，不管未 来是AI主导还是医生主场，科技巨头的卡位赛已全力冲刺。 那么，我们到底该怎么看这场热闹？说到底，技术变革总会伴随着争议，但资本市场永远快人一步。至 于未来看病会不会真的靠机器人，咱们慢慢看。 ...

据交易所数据显示， 泓博医药4天3板。该股今日于14时50分封涨停，成交额22.86亿元，换手率 30.48%。金融界App AI线索挖掘：近期 AI医疗概念受到市场关注，相关领域动态频出。摩根大通医疗 健康大会期间，英伟达与礼来宣布将在五年内斥资10亿美元建立联合研究实验室，加速AI药物研发进 程。泓博医药专注于小分子 创新药物研发与生产，业务覆盖药物发现、合成工艺开发及商业化生产等 环节，属于AI医药细分领域，其业务模式与AI药物研发的行业趋势相契合，受到市场关注。 风险提 示：连板股波动剧烈，注意追高风险，理性投资！（注：以上由AI基于交易所等公开数据生成，内容 不构成投资建议。） ...

据天眼查APP显示，上海泓博智源医药股份有限公司成立于2007年12月14日，注册资本13958.6605万人 民币。 （文章来源：证券时报网） 数据宝统计，截至10:52，泓博医药成交额15.56亿元，创上市以来新高。最新股价上涨9.11%，换手率 21.11%。上一交易日该股全天成交额为3.24亿元。 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Market Overview - The market experienced fluctuations throughout the day, with significant divergence in the commercial aerospace sector, leading to several stocks like China Satellite Communications and Aerospace Science and Technology hitting the daily limit down [1] - AI applications saw a strengthening trend, particularly in AI healthcare and AI pharmaceuticals, with stocks such as Meinian Health and Hongbo Pharmaceutical reaching the daily limit up [1] - The overall market saw approximately 3,700 stocks decline, with a total transaction volume of 3.7 trillion, setting a new historical record [1] - The Shanghai Composite Index closed down by 0.64%, the Shenzhen Component Index by 1.37%, and the ChiNext Index by 1.96% [1] AI Healthcare and Pharmaceuticals - AI applications in healthcare showed strong performance initially, with notable stocks like Meinian Health and Di'an Diagnostics achieving consecutive gains [3] - Nvidia and Eli Lilly announced a partnership to invest $1 billion over five years to establish a joint research lab in the San Francisco Bay Area, aimed at accelerating AI applications in the pharmaceutical industry [3] Consumer Sector - The consumer sector showed strength, with stocks like Sanjiang Shopping and Mingpai Jewelry achieving consecutive gains [5] - Walmart and Google announced a collaboration to integrate Google's generative AI chatbot into Walmart's shopping process, enhancing consumer experience [5] Oil Sector - The oil sector saw a strong early surge, with stocks like Delong Energy and Shandong Molong hitting the daily limit up [8] - The geopolitical situation in Iran may significantly impact oil production and exports, potentially affecting oil prices in the long term [8] Electric Grid Sector - The electric grid sector experienced a surge, with stocks like Sanbian Technology and TBEA hitting the daily limit up [10] - A transformer explosion in Cleveland, Ohio, led to power outages, contributing to the sector's positive performance [10] Additional Sectors - Other sectors such as lithium batteries, autonomous driving, and brokerage firms also showed notable movements during the trading session [12]